Hester Biosciences Limited has received the manufacturing license from the Food & Drugs Control Administration to manufacture and market the Low Pathogenic Avian Influenza Vaccine, Inactivated H9N2 strain for poultry.

Low Pathogenic Avian Influenza H9N2 strain has been a persistent challenge in poultry flocks and is known to cause year-round comorbidity, leading to significant economic losses. H9N2 can lead to an irreversible drop in egg production in layers and performance loss in broilers. It can also lead to high mortality in the presence of other infections.

This license is a key regulatory milestone in advancing Hester's prevention-led poultry healthcare portfolio.

This vaccine has been developed from technology acquired from ICAR-NIHSAD via Agrinnovate India.